Overview
Financial overview
Equity research
DT’s CMD outlined strategy for the next five years. SBU might be in some ways the most mature application area, but its volume recovery will be crucial to earnings in the short-term.
DT’s Q3 wasn’t strong yet EBITA was better than estimated; Q4 should see further gradual gains, while next year has significant earnings drivers after a period of low volumes.
DT’s Q3 was challenging, but the bottom line result was a bit better than expected as the EUR 2.8m adjusted EBITA was slightly higher than estimated. Q4 will still be on the soft side while growth is set to resume already early next year as DT sees Q1’26 top line growing at a double-digit rate.
DT reports Q3 results on Oct 30. Q3 will be another weak quarter, while Q4 could be relatively better. DT’s earnings slump this year, but valuation is quite low relative to potential.
DT’s Q2 earnings were softer than estimated and disappointingly Q3 results too are about to decline, yet fundamental demand drivers should remain strong for FY’26.
DT’s Q2 revenue was slightly higher than expected, however the EUR 1.7m EBITA fell short of estimates as sales mix turned out to be even more unfavorable than estimated. Security CT sales should be back on track by the end of the year, yet DT’s outlook for H2 is softer than previously expected.
DT reports Q2 results on Aug 7. Q2 will not be great, and DT may not see earnings growth before Q4, but multiples are already relatively low on this year’s soft earnings while medium-term growth drivers remain intact.
DT’s Q1 results were soft relative to estimates and earnings may not grow over the next two quarters, but valuation is low especially if SBU starts to grow again later this year.
DT’s Q1 was expected to remain slightly muted, but the reported figures were clearly lower than estimated. DT’s short-term outlook has also softened mainly due to a prolonged dip in security applications demand.
DT reports Q1 results on Apr 24. We make minor revisions at this point as the trade war’s eventual outcome remains open.
Annual financials
Quarterly financials
Assets
Equity and liabilities
Cashflow
Environment
Social
Governance
Videos
Annual and sustainability reports
- Annual review 2024
- Annual review 2023
- Annual review 2022
- Annual review 2021
- Annual review 2020
- Annual review 2019
- Annual review 2018
Company news
Detection Technology Plc Managers' Transactions 26 November 2025 at 17:00 (EET)
Detection Technology Plc - Managers' Transactions
Person subject to the notification requirement
Name: Antti Holopainen
Position: Closely associated person
(1): Person Discharging Managerial Responsibilities In Issuer
Name: Sari Holopainen
Position: Other senior manager
Issuer: Detection Technology Plc
LEI: 743700IXKYKNXJ6BFL39
Notification type: AMENDMENT
Reference number: 131498/5/4
Amendment comment: Venue corrected
____________________________________________
Transaction date: 2025-11-21
Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)
Instrument type: SHARE
ISIN: FI4000115464
Nature of transaction: ACQUISITION
Transaction details
(1): Volume: 2,000 Unit price: 10.4913 EUR
Aggregated transactions (1):
Volume: 2,000 Volume weighted average price: 10.4913 EUR
Further information
Hannu Martola, President and CEO
+358 500 449 475, hannu.martola@deetee.com
Nordea is the company's Certified Advisor under the Nasdaq First North GM rules, +358 9 5300 6774
Detection Technology is a global provider of X-ray detector solutions and services for medical, security, and industrial applications. The company's solutions range from sensor components to optimized detector subsystems with ASICs, electronics, mechanics, software, and algorithms. It has sites in Finland, China, France, India, and the US. The company's shares are listed on Nasdaq First North Growth Market Finland under the ticker symbol DETEC.
Distribution: Nasdaq Helsinki, key media, www.deetee.com
Detection Technology Plc Managers' Transactions 26 November 2025 at 17:00 (EET)
Detection Technology Plc - Managers' Transactions
Person subject to the notification requirement
Name: Hannu Martola
Position: President and CEO
Issuer: Detection Technology Plc
LEI: 743700IXKYKNXJ6BFL39
Notification type: INITIAL NOTIFICATION
Reference number: 131562/5/6
____________________________________________
Transaction date: 2025-11-21
Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)
Instrument type: SHARE
ISIN: FI4000115464
Nature of transaction: ACQUISITION
Transaction details
(1): Volume: 1,000 Unit price: 10.5 EUR
(2): Volume: 1,000 Unit price: 10.45 EUR
Aggregated transactions (2):
Volume: 2,000 Volume weighted average price: 10.475 EUR
____________________________________________
Transaction date: 2025-11-24
Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)
Instrument type: SHARE
ISIN: FI4000115464
Nature of transaction: ACQUISITION
Transaction details
(1): Volume: 1,000 Unit price: 10.75 EUR
Aggregated transactions (1):
Volume: 1,000 Volume weighted average price: 10.75 EUR
Further information
Hannu Martola, President and CEO
+358 500 449 475, hannu.martola@deetee.com
Nordea is the company's Certified Advisor under the Nasdaq First North GM rules, +358 9 5300 6774
Detection Technology is a global provider of X-ray detector solutions and services for medical, security, and industrial applications. The company's solutions range from sensor components to optimized detector subsystems with ASICs, electronics, mechanics, software, and algorithms. It has sites in Finland, China, France, India, and the US. The company's shares are listed on Nasdaq First North Growth Market Finland under the ticker symbol DETEC.
Distribution: Nasdaq Helsinki, key media, www.deetee.com
Detection Technology Plc company announcement 17 November 2025 at 18:00 (EET)
Detection Technology announces its new strategy
Detection Technology Plc has updated its strategy for 2026-2030. In line with the DT2030 strategy, the company aims to outgrow the global X-ray detector market by increasing added-value and focusing on the fastest-growing imaging applications. The company's mid-term financial targets remain unchanged.
The DT2030 strategy builds on the company's core strengths, and its implementation reinforces the company's position as a global leader in X-ray detector solutions. The company seeks new growth through smart, data-generating, and higher value-added solutions to provide its customers with exceptional usability and service experience.
The DT2030 strategic levers are:
- Relentlessly improve current business and operations, and develop capabilities to strengthen profitability and competitiveness
- Drive the TFT X-ray flat panel detector business across different application areas and new geographical markets
- Commercialize more value-added integrated hardware-software solutions to a broader customer base
- Seek new opportunities beyond the current business scope, including photon counting and software solutions
- Being the most trusted partner that drives customer success through exceptional usability
- Elevate performance culture that promotes development and efficiency
Detection Technology's financial targets:
Detection Technology aims to increase its sales by at least 10% per annum and to achieve an operating margin (EBITA) of 15% in the medium term. The company aims to distribute 30-60% of the Group's annual result to shareholders as dividends.
Detection Technology will host the Capital Markets Day on 18 November 2025 starting at 12:30 EET. At the event, the company's new DT2030 strategy will be introduced, along with its business, market developments, growth opportunities, and the technological and production capabilities that strengthen its competitiveness. The event program and registration details are available on the company's website.
Further information
Hannu Martola, President and CEO
+358 500 449 475, hannu.martola@deetee.com
Nordea is the company's Certified Advisor under the Nasdaq First North GM rules, +358 9 5300 6774
Detection Technology is a global provider of X-ray detector solutions and services for medical, security, and industrial applications. The company's solutions range from sensor components to optimized detector subsystems with ASICs, electronics, mechanics, software, and algorithms. It has sites in Finland, China, France, India, and the US. The company's shares are listed on Nasdaq First North Growth Market Finland under the ticker symbol DETEC.
Distribution: Nasdaq Helsinki, key media, www.deetee.com
Detection Technology Plc company announcement 30 October 2025 at 09:00 (EET)
DETECTION TECHNOLOGY PLC BUSINESS REVIEW JANUARY-SEPTEMBER 2025
Detection Technology Q3 2025: A challenging quarter, but the sentiment is improving
July-September 2025 highlights
- Net sales decreased by -8.8% to EUR 24.7 million (27.1)
- Net sales of Americas decreased by -67.7% to EUR 0.6 million (2.0)
- Net sales of APAC (Asia-Pacific) decreased by -5.8% to EUR 16.6 million (17.6)
- Net sales of EMEIA (Europe, Middle East, India and Africa) decreased by -0.2% to EUR 7.5 million (7.5)
- Net sales of industrial applications decreased by -9.2% to EUR 4.5 million (4.9)
- Net sales of medical applications decreased by -4.5% to EUR 10.4 million (10.9)
- Net sales of security applications decreased by -12.8% to EUR 9.8 million (11.3)
- Operating profit (EBITA) excluding non-recurring items (NRI) was EUR 2.8 million (4.2)
- Operating margin (EBITA-%) excluding NRI was 11.4% of net sales (15.3%)
- Operating profit (EBITA) was EUR 2.5 million (4.2)
- Operating margin (EBITA-%) was 10.0% of net sales (15.3%)
- Return on investment (ROI, 12-month rolling) was 12.2% (17.0%)
January-September 2025 highlights
- Net sales decreased by -6.0% to EUR 71.3 million (75.9)
- Net sales of Americas decreased by -32.9% to EUR 3.0 million (4.5)
- Net sales of APAC increased by 1.5% to EUR 50.8 million (50.0)
- Net sales of EMEIA decreased by -18.0% to EUR 17.6 million (21.4)
- Net sales of industrial applications decreased by -0.5% to EUR 13.8 million (13.9)
- Net sales of medical applications increased by 7.1% to EUR 31.8 million (29.7)
- Net sales of security applications decreased by -20.4% to EUR 25.8 million (32.3)
- Operating profit (EBITA) excluding non-recurring items (NRI) was EUR 5.9 million (9.7)
- Operating margin (EBITA-%) excluding NRI was 8.3% of net sales (12.8%)
- Operating profit (EBITA) was EUR 5.6 million (9.7)
- Operating margin (EBITA-%) was 7.8% of net sales (12.8%)
UNAUDITED (Figures in parentheses refer to the corresponding period of the previous year.)
Business outlook
Detection Technology expects a single-digit year-on-year decline in total net sales for Q4 2025 and double-digit growth in Q1 2026.
The geopolitical situation, new U.S. import tariffs, U.S. relations with other countries, China's healthcare reform, and price competition especially in China create uncertainty.
Detection Technology aims to increase its sales by at least 10% per annum and to achieve an operating margin (EBITA) of 15% in the medium term.
President and CEO, Hannu Martola:
The third quarter was as challenging as anticipated. Sales declined across all application areas and geographical markets. Although nearly half of the decrease was due to currency fluctuations, we have taken actions to turn the tide and refocused our resources. We are now moving toward renewed growth as the markets are picking up.
The largest dent in our sales came from security applications. In the Americas, the sales outcome was temporarily weak in Q3, mirroring the sales development of certain key customers. In Europe, a major OEM customer was temporarily depleting its inventories. However, EMEIA's total net sales remained flat as growth in industrial applications offset the decline in security.
The decline in APAC sales was mainly due to the loss of legacy industrial line scanner sales in China because of intense competition. Demand for medical CT (computed tomography) applications continued to grow in China, but material constraints limited our delivery capability. In contrast, sales of security applications increased. Currency exchange rate fluctuations weakened the already soft performance, and total net sales in the APAC region fell slightly short of expectations.
A bright spot of the review period was the strong growth in industrial flat panel detector sales in China. Our position also remained strong in medical and security CT applications in both the APAC and EMEIA regions.
Our profitability improved compared to the previous quarter, and the EBITA margin was double digits. However, it fell short of the comparison period due to the decline in sales and a change in the product mix. We have implemented the necessary cost-saving measures to reach our target level and to focus resources on growth areas that support our long-term strategy. The one-time costs (NRI) related to these changes were EUR 0.3 million.
We believe that we have passed the turning point. Medical and security CT applications are expected to see stronger demand toward the end of the year and into 2026. Industrial demand should remain robust, particularly for our flat panel detectors.
As previously estimated, our Q4 total net sales are expected to decline by a single-digit percentage, which means a flat outcome in comparable currencies. APAC sales are expected to remain at the level of the comparison period, while sales in EMEIA and the Americas are expected to decline. When estimating sales development by main applications, we expect medical and industrial to grow, and security to decline. All regions and applications are nevertheless expected to grow compared to the previous quarter. We expect total net sales in Q4 to grow by double digits compared to Q3. Based on our outlook, Q1 of 2026 will mark a return to growth, and we anticipate double-digit growth in total net sales.
Key figures
| (EUR 1,000) | 7-9/2025 | 7-9/2024 | 1-9/2025 | 1-9/2024 | 1-12/2024 |
| Net sales | 24,717 | 27,103 | 71,338 | 75,901 | 107,514 |
| Change in net sales, % | -8.8% | 10.6% | -6.0% | 4.7% | 3.6% |
| EBITA excluding NRI | 2,807 | 4,157 | 5,908 | 9,726 | 14,892 |
| EBITA excluding NRI, % | 11.4% | 15.3% | 8.3% | 12.8% | 13.9% |
| Non-recurring items (NRI) | -342 | 0 | -342 | 0 | 0 |
| EBITA | 2,465 | 4,157 | 5,566 | 9,726 | 14,892 |
| EBITA, % | 10.0% | 15.3% | 7.8% | 12.8% | 13.9% |
| R&D costs | 2,723 | 2,694 | 8,504 | 8,255 | 11,379 |
| R&D costs, % of net sales | 11.0% | 9.9% | 11.9% | 10.9% | 10.6% |
| Cash flow from operating activities | 492 | 6,415 | 2,389 | 13,242 | 20,133 |
| Net interest-bearing debt at end of period | -19,800 | -20,797 | -19,800 | -20,797 | -27,767 |
| Investments | 504 | 248 | 2,052 | 1,733 | 2,218 |
| Return on investment (ROI), % | 12.2% | 17.0% | 12.2% | 17.0% | 17.4% |
| Gearing, % | -26.5% | -27.1% | -26.5% | -27.1% | -33.6% |
| Earnings per share, EUR | 0.11 | 0.22 | 0.22 | 0.48 | 0.76 |
| Earnings per share (diluted), EUR | 0.11 | 0.22 | 0.22 | 0.48 | 0.76 |
| Number of shares at the end of the period | 14,655,630 | 14,655,930 | 14,655,630 | 14,655,930 | 14,655,930 |
| Weighted average number of shares outstanding | 14,655,630 | 14,655,930 | 14,655,697 | 14,655,930 | 14,655,930 |
| Weighted average number of shares outstanding, diluted | 14,655,630 | 14,666,184 | 14,657,172 | 14,661,289 | 14,660,744 |
The development of net sales
In Q3 2025, Detection Technology's total net sales decreased by -8.8% (10.6%) and amounted to EUR 24.7 (27.1) million. Net sales decreased across all application areas and geographical markets. The decline was mainly due to exchange rate fluctuations and a decrease in demand for security applications.
Sales in security applications declined significantly in the Americas due to the sales development of certain key customers and in Europe as a result of temporary inventory reductions by an OEM customer. However, EMEIA sales remained at the level of the comparison period, supported by growth in industrial sales.
The decline in legacy industrial line-scan application sales had a significant impact on the decrease in APAC sales. Demand for medical CT applications continued to grow in China, but material constraints limited deliveries. Sales in security applications increased, and sales of flat panel detectors strengthened in China, but these were not sufficient to offset the overall loss in APAC sales.
The APAC business unit's net sales decreased by -5.8% (6.5%) to EUR 16.6 (17.6) million. The EMEIA business unit's net sales decreased by -0.2% (33.1%) to EUR 7.5 (7.5) million. The Americas business unit's net sales decreased by -67.7% (-14.5%) to EUR 0.6 (2.0) million. APAC accounted for 67.1% (65.0%) of the company's total net sales, EMEIA 30.2% (27.6%), and the Americas 2.6% (7.4%).
Net sales from medical applications decreased by -4.5% (0.6%) to EUR 10.4 (10.9) million. Net sales from security applications decreased by -12.8% (16.2%) to EUR 9.8 (11.3) million. Net sales from industrial applications decreased by -9.2% (24.0%) to EUR 4.5 (4.9) million. Medical applications accounted for 42.0% (40.2%) of the company's total net sales, security applications 39.8% (41.7%), and industrial applications 18.1% (18.2%).
In Q3, the share of the five largest customers in Detection Technology's total net sales was 53.4% (56.9%).
In January-September 2025, the company's total net sales decreased by -6.0% (4.7%) and were EUR 71.3 (75.9) million. Net sales of APAC increased by 1.5% (3.7%) to EUR 50.8 (50.0) million. Net sales of EMEIA decreased by -18.0% (35.4%) to EUR 17.6 (21.4) million. Net sales of Americas decreased by -32.9% (-46.9%) to EUR 3.0 (4.5) million. APAC accounted for 71.2% (65.9%) of the company's total net sales, EMEIA 24.6% (28.2%), and the Americas 4.2% (5.9%).
Net sales from medical applications increased by 7.1% (-15.9%) to EUR 31.8 (29.7) million. Net sales from security applications decreased by -20.4% (24.1%) to EUR 25.8 (32.3) million. Net sales from industrial applications decreased by -0.5% (24.5%) to EUR 13.8 (13.9) million. Medical applications accounted for 44.6% (39.1%) of the company's total net sales, security applications 36.1% (42.6%), and industrial applications 19.3% (18.3%).
In January-September 2025, the share of the five largest customers in Detection Technology's total net sales was 54.6% (52.1%).
NET SALES BY BUSINESS UNITS
| (EUR 1,000) | 7-9/2025 | 7-9/2024 | Change, % | 1-9/2025 | 1-9/2024 | Change, % |
| Americas | 647 | 2,003 | -67.7% | 3,003 | 4,476 | -32.9% |
| APAC | 16,596 | 17,610 | -5.8% | 50,758 | 49,998 | 1.5% |
| EMEIA | 7,473 | 7,490 | -0.2% | 17,577 | 21,427 | -18.0% |
| TOTAL | 24,717 | 27,103 | -8.8% | 71,338 | 75,901 | -6.0% |
NET SALES BY MAIN APPLICATIONS
| (EUR 1,000) | 7-9/2025 | 7-9/2024 | Change, % | 1-9/2025 | 1-9/2024 | Change, % |
| Industrial | 4,478 | 4,930 | -9.2% | 13,797 | 13,872 | -0.5% |
| Medical | 10,391 | 10,882 | -4.5% | 31,783 | 29,680 | 7.1% |
| Security | 9,848 | 11,291 | -12.8% | 25,758 | 32,349 | -20.4% |
| TOTAL | 24,717 | 27,103 | -8.8% | 71,338 | 75,901 | -6.0% |
Events during the review period
In Q3, Detection Technology took measures to improve profitability and competitiveness. The company adjusted its business to invest in focus areas that strengthen its competitiveness and position in international markets. The purpose of these changes is to streamline and accelerate business operations, enhance the offering, and improve customer focus.
As part of these actions, the company launched change negotiations in Finland under the Act on Co-operation within Undertakings, citing production-related and financial reasons. The negotiations were concluded on 2 September 2025, leading to a total of seven position reductions, an organizational change, and some task reallocations.
The company implemented efficiency and reorganization measures across its global sites. Consequently, a total of six employments were terminated in China. All measures were completed by the end of the review period.
Following the cost-saving program, the company recorded non-recurring items (NRI) totaling EUR 0.3 million (0.0) in Q3. The NRI was related to the reduction in personnel. The company estimates that the measures will result in total cost savings of approximately EUR 0.4 million in H2 of 2025 and EUR 1.5 million in fiscal year 2026.
DT2030 strategy and Capital Markets Day
Detection Technology's current strategy period will end at the close of 2025, and the new strategy will extend through 2030. In line with the DT2030 strategy, the company aims to outgrow the market.
The DT2030 strategy builds on the company's core strengths and reinforces its position as a global leader in X-ray detector solutions. The company focuses on its main application areas and seeks new growth through smarter and higher value-added solutions to provide its customers with exceptional usability and service experience.
Detection Technology will host the Capital Markets Day on 18 November 2025. At the event, the company's new DT2030 strategy will be introduced, along with its business, market developments, growth opportunities, and the technological and production capabilities that strengthen its competitiveness. The event program and registration details are available on the company's website.
Financial statements review 2025
Detection Technology will publish its financial statements review for 2025 on Thursday 5 February 2026.
Board of Directors, Detection Technology Plc
Further information
President and CEO Hannu Martola will be available for interviews and further information on the release date at 9:00-11:00 (EET).
Hannu Martola, President and CEO
+358 500 449 475, hannu.martola@deetee.com
Nordea is the company's Certified Advisor under the Nasdaq First North GM rules, +358 9 5300 6774
Detection Technology is a global provider of X-ray detector solutions and services for medical, security, and industrial applications. The company's solutions range from sensor components to optimized detector subsystems with ASICs, electronics, mechanics, software, and algorithms. It has sites in Finland, China, France, India, and the US. The company's shares are listed on Nasdaq First North Growth Market Finland under the ticker symbol DETEC.
Distribution: Nasdaq Helsinki, key media, www.deetee.com
Detection Technology Plc company announcement 24 September 2025 at 09:00 (EEST)
Detection Technology's financial calendar for 2026
Detection Technology Plc will disclose the following financial releases in 2026:
- Financial statements review 2025: 5 February 2026
- Business review January-March 2026: 23 April 2026
- Half-yearly report January-June 2026: 6 August 2026
- Business review January-September 2026: 29 October 2026
The financial statements and annual review for 2025 will be published on 5 March 2026. The Annual General Meeting is scheduled for 26 March 2026. The Board of Directors of the company will convene the meeting.
Detection Technology's financial calendar can be found from the company's website at https://www.deetee.com/ir-services/.
Further information
Hannu Martola, President and CEO
+358 500 449 475, hannu.martola@deetee.com
Nordea is the company's Certified Advisor under the Nasdaq First North GM rules, +358 9 5300 6774
Detection Technology is a global provider of X-ray detector solutions and services for medical, security, and industrial applications. The company's solutions range from sensor components to optimized detector subsystems with ASICs, electronics, mechanics, software, and algorithms. It has sites in Finland, China, France, India, and the US. The company's shares are listed on Nasdaq First North Growth Market Finland under the ticker symbol DETEC.
Distribution: Nasdaq Helsinki, key media, www.deetee.com
Detection Technology Plc company announcement 15 September 2025 at 09:00 (EEST)
Shareholders' Nomination Board appointed at Detection Technology
A Shareholders' Nomination Board has been appointed at Detection Technology, based on holdings as of 1 September 2025. Chair of the Board of A. Ahlström, Peter Seligson, has been appointed Chair of the Nomination Board as the representative of Ahlstrom Capital BV. Head of Investments at OP Varainhoito, Tomi Viia, representing the OP mutual funds, and Director of Sustainability at Aktia, Niina Arkko, representing the Aktia mutual funds, have been appointed as Members.
Henrik Roos, Chair of Detection Technology's Board of Directors, serves as an expert on the Nomination Board. The organizing meeting of the Nomination Board was held on 12 September 2025.
The Shareholders' Nomination Board is responsible for preparing and presenting proposals to the General Meeting concerning the remuneration and number of members of the Board of Directors, as well as proposals for appointing members of the Board. The Nomination Board will submit its proposals for the next Annual General Meeting (AGM) to the Board of Directors of Detection Technology no later than 30 January 2026.
The Nomination Board consists of three members appointed by the company's three largest shareholders, each of which is entitled to nominate one member. The largest shareholders are determined based on the holdings listed in the shareholders' register of the company maintained by Euroclear Finland Ltd as of the first working day in September preceding the next AGM. The Chair of the Board of Detection Technology serves on the Nomination Board as an expert but is not an official member of the Nomination Board and does not have voting rights.
Detection Technology Plc
Further information
Hannu Martola, President and CEO
+358 500 449 475, hannu.martola@deetee.com
Nordea is the company's Certified Advisor under the Nasdaq First North GM rules, +358 9 5300 6774
Detection Technology is a global provider of X-ray detector solutions and services for medical, security, and industrial applications. The company's solutions range from sensor components to optimized detector subsystems with ASICs, electronics, mechanics, software, and algorithms. It has sites in Finland, China, France, India, and the US. The company's shares are listed on Nasdaq First North Growth Market Finland under the ticker symbol DETEC.
Distribution: Nasdaq Helsinki, key media, www.deetee.com
Detection Technology Plc company announcement 7 August 2025 at 09:00 (EEST)
DETECTION TECHNOLOGY PLC HALF-YEARLY REPORT JANUARY-JUNE 2025
Detection Technology Q2 2025: Sales declined, yet the company's market position remained solid
April-June 2025 highlights
- Net sales decreased by -6.6% to EUR 24.4 million (26.1)
- Net sales of Americas decreased by -5.2% to EUR 1.5 million (1.6)
- Net sales of APAC (Asia-Pacific) increased by 8.6% to EUR 18.2 million (16.7)
- Net sales of EMEIA (Europe, Middle East, India and Africa) decreased by -39.6% to EUR 4.7 million (7.8)
- Net sales of industrial applications increased by 4.2% to EUR 5.6 million (5.3)
- Net sales of medical applications increased by 13.9% to EUR 10.6 million (9.3)
- Net sales of security applications decreased by -28.2% to EUR 8.2 million (11.5)
- Operating profit (EBITA) was EUR 1.7 million (3.3)
- Operating margin (EBITA-%) was 7.0% of net sales (12.7%)
- Return on investment (ROI, 12-month rolling) was 14.7% (13.9%)
January-June 2025 highlights
- Net sales decreased by -4.5% to EUR 46.6 million (48.8)
- Net sales of Americas decreased by -4.8% to EUR 2.4 million (2.5)
- Net sales of APAC increased by 5.5% to EUR 34.2 million (32.4)
- Net sales of EMEIA decreased by -27.5% to EUR 10.1 million (13.9)
- Net sales of industrial applications increased by 4.2% to EUR 9.3 million (8.9)
- Net sales of medical applications increased by 13.8% to EUR 21.4 million (18.8)
- Net sales of security applications decreased by -24.4% to EUR 15.9 million (21.1)
- Operating profit (EBITA) was EUR 3.1 million (5.6)
- Operating margin (EBITA-%) was 6.7% of net sales (11.4%)
UNAUDITED (Figures in parentheses refer to the corresponding period of the previous year.)
Business outlook
Detection Technology expects a single digit year-on-year net sales decline in Q3 and H2 of 2025.
The geopolitical situation, new U.S. import tariffs, U.S. relations with other countries, China's healthcare reform, and price competition especially in China create uncertainty.
Detection Technology aims to increase its sales by at least 10% per annum and to achieve an operating margin (EBITA) of 15% in the medium term.
President and CEO, Hannu Martola:
"Our Q2 total net sales were a disappointment. Security CT system installations nearly halted in Europe, and EMEIA sales declined sharply. Over half of the sales decline was due to currency fluctuations. However, our position in key markets remained stable. We also maintained strong momentum in flat panel detector sales and strategic execution.
Demand for medical CT applications strengthened, particularly in China, where the backlog from healthcare reforms continued to clear. Sales of our flat panel detector portfolio for industrial applications also developed strongly, growing approximately 40% year-on-year in H1.
In contrast, the dip in demand for security applications was deeper than expected, leading to a sharp decline in EMEIA sales. The halt in security CT system installations in aviation in Europe-partly due to the so-called 100 ml liquid rule-weighed on performance. The strong comparison period also added pressure to the topline. Despite softer-than-expected sales, our market position in security CT remained intact.
Lower-than-expected quarterly sales and a less favorable sales mix eroded our profitability. Our profitability development has been unsatisfactory. To that end, appropriate cost measures are now being taken.
In Q2, we rolled out several notable products. Sales of the X-Panel 43108 flat panel detector, launched for single-scan imaging of large components in the automotive, aerospace, and defense industries, have started off successfully. We also introduced the X-Cargo for high-speed, high-energy cargo and industrial imaging. Supporting scanning speeds up to 70 km/h, the solution is already selling well for border security applications.
The expansion of our operations in India is progressing. The production facility has been completed, and the first products have been tested. We also invested in new technology to support long-term innovations and growth.
We are renewing our strategy for the next five-year period. We will deliver smart X-ray detector solutions that drive customer success through exceptional usability to outgrow the market. We continue to work on the strategy details and execution planning.
Looking ahead, we expect demand in both medical and security CT applications to start normalizing. In China, the recovery in medical demand continues following anti-corruption measures, but the new block purchasing model is intensifying competition. The regulatory bottleneck in European aviation will move away, as testing specifications for CT systems have been approved, and the equipment from a certain OEM has been recertified. We expect the security CT sales to be back on track by the end of the year. Industrial demand, particularly in defense, is increasing. However, visibility remains limited due to the impact of new tariffs, ongoing macroeconomic uncertainty, and constrained availability of certain electronic components.
In Q3, the APAC region indicates strengthening medical demand, but our sales are constrained mainly by component availability and therefore will remain stable. Demand for security applications is picking up slowly, leading to flat sales in EMEIA, while sales in the Americas are expected to decline by double digits. Following an estimated 5% currency impact, we expect year-on-year total net sales to decline by a single digit in Q3 and H2 of 2025."
Key figures
| (EUR 1,000) | 4-6/2025 | 4-6/2024 | 1-6/2025 | 1-6/2024 | 1-12/2024 |
| Net sales | 24,372 | 26,093 | 46,621 | 48,799 | 107,514 |
| Change in net sales, % | -6.6% | 3.5% | -4.5% | 1.7% | 3.6% |
| EBITA | 1,702 | 3,306 | 3,101 | 5,570 | 14,892 |
| EBITA, % | 7.0% | 12.7% | 6.7% | 11.4% | 13.9% |
| R&D costs | 3,146 | 3,049 | 5,781 | 5,560 | 11,379 |
| R&D costs, % of net sales | 12.9% | 11.7% | 12.4% | 11.4% | 10.6% |
| Cash flow from operating activities | 458 | 3,911 | 1,897 | 6,827 | 20,133 |
| Net interest-bearing debt at end of period | -19,794 | -14,744 | -19,794 | -14,744 | -27,767 |
| Investments | 1,144 | 352 | 1,548 | 1,485 | 2,218 |
| Return on investment (ROI), % | 14.7% | 13.9% | 14.7% | 13.9% | 17.4% |
| Gearing, % | -27.2% | -19.9% | -27.2% | -19.9% | -33.6% |
| Earnings per share, EUR | 0.07 | 0.15 | 0.11 | 0.26 | 0.76 |
| Earnings per share (diluted), EUR | 0.07 | 0.15 | 0.11 | 0.26 | 0.76 |
| Number of shares at the end of the period | 14,655,630 | 14,655,930 | 14,655,630 | 14,655,930 | 14,655,930 |
| Weighted average number of shares outstanding | 14,655,630 | 14,655,930 | 14,655,730 | 14,655,930 | 14,655,930 |
| Weighted average number of shares outstanding, diluted | 14,655,630 | 14,661,754 | 14,657,943 | 14,658,842 | 14,660,744 |
Q2 2025 webcast
Hannu Martola, the President and CEO of Detection Technology, will present the Q2 and January-June 2025 financial performance and events to analysts, investors, and media at a webcast. The live webcast in English will begin on 7 August 2025 at 13:00 (EEST).
A link to the webcast is available on the company's website (investors, webcasts). A recording of the webcast will be available later on the same webcasts page.
This release is a summary of Detection Technology's half-yearly report January-June 2025. The complete report can be found attached to the release and on the company's website.
Board of Directors, Detection Technology Plc
Further information
President and CEO Hannu Martola will be available for interviews and further information on the release date at 9:00-11:00 (EEST).
Hannu Martola, President and CEO
+358 500 449 475, hannu.martola@deetee.com
Nordea is the company's Certified Advisor under the Nasdaq First North GM rules, +358 9 5300 6774
Detection Technology is a global provider of X-ray detector solutions and services for medical, security, and industrial applications. The company's solutions range from sensor components to optimized detector subsystems with ASICs, electronics, mechanics, software, and algorithms. It has sites in Finland, China, France, India, and the US. The company's shares are listed on Nasdaq First North Growth Market Finland under the ticker symbol DETEC.
Distribution: Nasdaq Helsinki, key media, www.deetee.com
Detection Technology Plc inside information 17 June 2025 at 17:00 (EEST)
Inside information, profit warning: Detection Technology lowers its net sales guidance for Q2 2025
Detection Technology lowers its guidance for Q2 2025 and expects total net sales to decline by high single digits compared to the corresponding period last year. The main reason for this is the postponement of security X-ray system deployments in the EMEIA region (Europe, the Middle East, India, and Africa). The company maintains its net sales guidance for Q3 2025 unchanged.
New business outlook:
Detection Technology expects its total net sales to decline by high single digits year-on-year in Q2 2025 and to remain stable year-on-year in Q3 2025.
Geopolitical situation, new US import tariffs, U.S.-China relations, U.S.-EU relations, global economy, China's healthcare reform, price competition especially in China, the indirect impacts of the war in Ukraine, and events in the Middle East create uncertainty.
Detection Technology aims to increase its sales by at least 10% per annum and to achieve an operating margin (EBITA) of 15% in the medium term.
Previous business outlook (issued on 24 April 2025):
Detection Technology expects its year-on-year total net sales to remain stable in Q2 and Q3 of 2025.
Detection Technology has refined its earlier estimate of double-digit total net sales growth for Q2 2025 (published on 6 February 2025) and now expects sales to be at the same level as in the comparison period. The main reasons for this are exchange rate changes and the postponement of security system deployments.
Geopolitical situation, new US import tariffs, U.S.-China relations, U.S.-EU relations, global economy, China's healthcare reform, price competition especially in China, the indirect impacts of the war in Ukraine, and events in the Middle East create uncertainty.
Detection Technology aims to increase its sales by at least 10% per annum and to achieve an operating margin (EBITA) of 15% in the medium term.
Detection Technology will publish the half-yearly report on 7 August 2025.
Further information
Hannu Martola, President and CEO
+358 500 449 475, hannu.martola@deetee.com
Nordea is the company's Certified Advisor under the Nasdaq First North GM rules, +358 9 5300 6774
Detection Technology is a global provider of X-ray detector solutions and services for medical, security, and industrial applications. The company's solutions range from sensor components to optimized detector subsystems with ASICs, electronics, mechanics, software, and algorithms. It has sites in Finland, China, France, India, and the US. The company's shares are listed on Nasdaq First North Growth Market Finland under the ticker symbol DETEC.
Distribution: Nasdaq Helsinki, key media, www.deetee.com
Detection Technology Plc Managers' Transactions 3 June 2025 at 17:00 (EEST)
Detection Technology Plc - Managers' Transactions
Person subject to the notification requirement
Name: Antti Vasara
Position: Vice Chair of the Board
Issuer: Detection Technology Plc
LEI: 743700IXKYKNXJ6BFL39
Notification type: INITIAL NOTIFICATION
Reference number: 110603/4/4
____________________________________________
Transaction date: 2025-06-02
Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)
Instrument type: SHARE
ISIN: FI4000115464
Nature of transaction: ACQUISITION
Transaction details
(1): Volume: 1400 Unit price: 12.6 EUR
(2): Volume: 400 Unit price: 12.6 EUR
(3): Volume: 6 Unit price: 12.6 EUR
Aggregated transactions (3):
Volume: 1806 Volume weighted average price: 12.6 EUR
Further information
Hannu Martola, President and CEO
+358 500 449 475, hannu.martola@deetee.com
Nordea is the company's Certified Advisor under the Nasdaq First North GM rules, +358 9 5300 6774
Detection Technology is a global provider of X-ray detector solutions and services for medical, security, and industrial applications. The company's solutions range from sensor components to optimized detector subsystems with ASICs, electronics, mechanics, software, and algorithms. It has sites in Finland, China, France, India, and the US. The company's shares are listed on Nasdaq First North Growth Market Finland under the ticker symbol DETEC.
Distribution: Nasdaq Helsinki, key media, www.deetee.com
Detection Technology Plc Managers' Transactions 3 June 2025 at 17:00 (EEST)
Detection Technology Plc - Managers' Transactions
Person subject to the notification requirement
Name: Jyrki Vainionpää
Position: Member of the Board
Issuer: Detection Technology Plc
LEI: 743700IXKYKNXJ6BFL39
Notification type: INITIAL NOTIFICATION
Reference number: 110602/8/4
____________________________________________
Transaction date: 2025-06-02
Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)
Instrument type: SHARE
ISIN: FI4000115464
Nature of transaction: ACQUISITION
Transaction details
(1): Volume: 100 Unit price: 12.6 EUR
(2): Volume: 1087 Unit price: 12.6 EUR
(3): Volume: 100 Unit price: 12.6 EUR
(4): Volume: 94 Unit price: 12.6 EUR
Aggregated transactions (4):
Volume: 1381 Volume weighted average price: 12.6 EUR
Further information
Hannu Martola, President and CEO
+358 500 449 475, hannu.martola@deetee.com
Nordea is the company's Certified Advisor under the Nasdaq First North GM rules, +358 9 5300 6774
Detection Technology is a global provider of X-ray detector solutions and services for medical, security, and industrial applications. The company's solutions range from sensor components to optimized detector subsystems with ASICs, electronics, mechanics, software, and algorithms. It has sites in Finland, China, France, India, and the US. The company's shares are listed on Nasdaq First North Growth Market Finland under the ticker symbol DETEC.
Distribution: Nasdaq Helsinki, key media, www.deetee.com
Detection Technology Plc company announcement 8 May 2025 at 09:00 (EEST)
Change in the management of Detection Technology
Bree Allen, President of the Americas Business Unit and a member of the management group at Detection Technology, is leaving his position with the Group as of 23 May 2025, relocating with his family to Colorado and pursuing new opportunities outside of the company. He has worked for Detection Technology at its Boston office since 2022.
Arve Lukander, President of the EMEIA (Europe, Middle East, India and Africa) Business Unit, will take on the responsibility of leading the Americas Business Unit. The change does not have an impact on the company's operating and financial reporting models.
"Bree Allen has played a key role in developing our business in the Americas. I would like to thank Bree for his contributions to the company and wish him every success in his future endeavours," says Hannu Martola, President and CEO of Detection Technology.
The members of Detection Technology's management group, as of 23 May 2025, will be
- Mr. Hannu Martola, President and CEO
- Mr. Matti Nylander, CFO
- Mr. Arve Lukander, President, EMEIA and Americas Business Units
- Mr. Chen Wu, President, APAC Business Unit
- Mr. Juha Talasmäki, Vice President, Business Development
- Ms. Sari Holopainen, Vice President, People and Culture
- Mr. Jyrki Still, CTO
- Mr. Kai Utela, Vice President, Operations
Detection Technology Plc
Further information
Hannu Martola, President and CEO
+358 500 449 475, hannu.martola@deetee.com
Nordea is the company's Certified Advisor under the Nasdaq First North GM rules, +358 9 5300 6774
Detection Technology is a global provider of X-ray detector solutions and services for medical, security, and industrial applications. The company's solutions range from sensor components to optimized detector subsystems with ASICs, electronics, mechanics, software, and algorithms. It has sites in Finland, China, France, India, and the US. The company's shares are listed on Nasdaq First North Growth Market Finland under the ticker symbol DETEC.
Distribution: Nasdaq Helsinki, key media, www.deetee.com
Detection Technology Plc company announcement 24 April 2025 at 09:00 (EEST)
DETECTION TECHNOLOGY PLC BUSINESS REVIEW JANUARY-MARCH 2025
Detection Technology Q1 2025: Growth in medical
January-March 2025 highlights
- Net sales decreased by -2.0% to EUR 22.2 million (22.7)
- Net sales of Americas decreased by -3.9% to EUR 0.9 million (0.9)
- Net sales of APAC (Asia-Pacific) increased by 2.1% to EUR 16.0 million (15.6)
- Net sales of EMEIA (Europe, Middle East, India and Africa) decreased by -12.2% to EUR 5.4 million (6.2)
- Net sales of industrial applications increased by 4.2% to EUR 3.8 million (3.6)
- Net sales of medical applications increased by 13.7% to EUR 10.8 million (9.5)
- Net sales of security applications decreased by -20.0% to EUR 7.7 million (9.6)
- Operating profit (EBITA) was EUR 1.4 million (2.3)
- Operating margin (EBITA-%) was 6.3% of net sales (10.0%)
UNAUDITED (Figures in parentheses refer to the corresponding period of the previous year.)
Business outlook
Detection Technology expects its year-on-year total net sales to remain stable in Q2 and Q3 of 2025.
Detection Technology has refined its earlier estimate of double-digit total net sales growth for Q2 2025 (published on 6 February 2025) and now expects sales to be at the same level as in the comparison period. The main reasons for this are exchange rate changes and the postponement of security system deployments.
Geopolitical situation, new US import tariffs, U.S.-China relations, U.S.-EU relations, global economy, China's healthcare reform, price competition especially in China, the indirect impacts of the war in Ukraine, and events in the Middle East create uncertainty.
Detection Technology aims to increase its sales by at least 10% per annum and to achieve an operating margin (EBITA) of 15% in the medium term.
President and CEO, Hannu Martola:
"The Q1 outcome, in the big picture, was as expected, although exchange rate fluctuations impacted sales toward the end of the quarter. We were particularly pleased that our medical sales returned to growth - a turnaround we have been anticipating for a long time. There are signs that the demand backlog caused by China's anti-corruption campaign has begun to ease, and our APAC sales increased slightly as a result. Furthermore, it was encouraging to see significant growth in TFT (thin-film transistor) flat panel detector sales in industrial applications.
At the same time, demand for security applications remained sluggish, and the dip was bigger than anticipated. A delay in aviation CT (computed tomography) system installations in Europe, partly due to regulatory reasons related to the so-called 100 ml liquid rule, negatively affected EMEIA sales. We believe this is a short-term dip, as our customers have indicated that their order backlog is strong. Security application demand was also weaker than expected in the Americas. Sudden exchange rate changes at the end of the quarter led to a slight decline in our total net sales.
The drop in net sales, a less favourable sales mix compared to the reference period, and the timing of other income and certain expenses resulted in modest profitability for Q1. Exchange rate fluctuations are affecting sales in EUR, but the impact on the result is mitigated by a similar currency mix in costs.
Global markets have become increasingly unstable and unpredictable, and the ongoing transformation in the dynamics of international trade is impacting our business. The direct impact of the new tariffs on our business currently appears to be limited, but indirect effects are difficult to foresee. In addition, currency fluctuations may affect our reported sales. Despite these challenges, we also see opportunities. Rising global insecurity is driving demand for X-ray imaging applications, and large-scale investments in the defense industry are opening new doors.
Due to significantly increased market uncertainty, we estimate that year-on-year total net sales will remain stable in Q2. Demand for medical applications remains good, especially in the APAC region. Demand for industrial applications is also developing positively. The temporary dip in demand for security applications appears to be prolonged and will negatively affect EMEIA sales in particular. In the Americas, we expect sales to return to growth in Q2. Visibility continues to be limited, creating uncertainty in the outlook for Q3. We expect Q3 total net sales to remain stable or show slight growth."
Key figures
| (EUR 1,000) | 1-3/2025 | 1-3/2024 | 1-12/2024 |
| Net sales | 22,249 | 22,706 | 107,514 |
| Change in net sales, % | -2.0% | -0.2% | 3.6% |
| EBITA | 1,399 | 2,263 | 14,892 |
| EBITA, % | 6.3% | 10.0% | 13.9% |
| R&D costs | 2,634 | 2,512 | 11,379 |
| R&D costs, % of net sales | 11.8% | 11.1% | 10.6% |
| Cash flow from operating activities | 1,412 | 2,980 | 20,133 |
| Net interest-bearing debt at end of period | -28,492 | -14,508 | -27,767 |
| Investments | 390 | 1,132 | 2,218 |
| Return on investment (ROI), % | 17.0% | 11.2% | 17.4% |
| Gearing, % | -38.2% | -20.3% | -33.6% |
| Earnings per share, EUR | 0.05 | 0.11 | 0.76 |
| Earnings per share (diluted), EUR | 0.05 | 0.11 | 0.76 |
| Number of shares at the end of the period | 14,655,630 | 14,655,930 | 14,655,930 |
| Weighted average number of shares outstanding | 14,655,830 | 14,655,930 | 14,655,930 |
| Weighted average number of shares outstanding, diluted | 14,660,256 | 14,655,930 | 14,660,744 |
The development of net sales
In Q1, Detection Technology's total net sales decreased by -2.0% (-0.2%) and amounted to EUR 22.2 (22.7) million. Medical sales returned to growth in China, where unmet demand caused by an anti-corruption campaign targeting healthcare providers began to ease. In contrast, demand for security applications weakened in Europe, where regulatory requirements contributed to delays in CT system installations in the aviation sector. Similarly, demand for security applications was weaker than expected in the Americas. Ultimately, total net sales declined slightly due to exchange rate changes at the end of the quarter.
The APAC business unit's net sales increased by 2.1% (2.5%) and were EUR 16.0 (15.6) million. The EMEIA business unit's net sales declined by -12.2% (23.5%) and were EUR 5.4 (6.2) million. The Americas business unit's net sales declined by -3.9% (-63.8%) and were EUR 0.9 (0.9) million. APAC accounted for 71.8% (68.9%) of the company's total net sales, EMEIA for 24.3% (27.1%), and the Americas for 3.9% (4.0%).
Net sales from medical applications increased by 13.7% (-20.9%) and were EUR 10.8 (9.5) million. Net sales from security applications decreased by -20.0% (31.5%) and were EUR 7.7 (9.6) million. Net sales from industrial applications grew by 4.2% (5.3%) and were EUR 3.8 (3.6) million. Medical applications accounted for 48.7% (42.0%) of total net sales, security applications 34.4% (42.2%), and industrial applications 16.9% (15.9%).
The share of the five largest customers in Detection Technology's total net sales was 61.5% (53.2%).
NET SALES BY BUSINESS UNITS
| (EUR 1,000) | 1-3/2025 | 1-3/2024 | Change, % | 1-12/2024 |
| Americas | 871 | 907 | -3.9% | 6,591 |
| APAC | 15,969 | 15,639 | 2.1% | 70,525 |
| EMEIA | 5,410 | 6,160 | -12.2% | 30,398 |
| TOTAL | 22,249 | 22,706 | -2.0% | 107,514 |
NET SALES BY MAIN APPLICATIONS
| (EUR 1,000) | 1-3/2025 | 1-3/2024 | Change, % | 1-12/2024 |
| Industrial | 3,754 | 3,603 | 4.2% | 19,038 |
| Medical | 10,832 | 9,525 | 13.7% | 42,190 |
| Security | 7,664 | 9,578 | -20.0% | 46,285 |
| TOTAL | 22,249 | 22,706 | -2.0% | 107,514 |
Half-yearly report 2025
Detection Technology will publish the half-yearly report on 7 August 2025.
Board of Directors, Detection Technology Plc
Further information
President and CEO Hannu Martola will be available for interviews and further information on the release date at 9:00-11:00 (EEST).
Hannu Martola, President and CEO
+358 500 449 475, hannu.martola@deetee.com
Nordea is the company's Certified Advisor under the Nasdaq First North GM rules, +358 9 5300 6774
Detection Technology is a global provider of X-ray detector solutions and services for medical, security, and industrial applications. The company's solutions range from sensor components to optimized detector subsystems with ASICs, electronics, mechanics, software, and algorithms. It has sites in Finland, China, France, India, and the US. The company's shares are listed on Nasdaq First North Growth Market Finland under the ticker symbol DETEC.
Distribution: Nasdaq Helsinki, key media, www.deetee.com
Detection Technology Plc company announcement 27 March 2025 at 18:15 (EET)
Detection Technology cancels shares held in the joint account
The Board of Directors of Detection Technology Plc has decided to cancel the shares held in the company's joint account, which were transferred to the company in accordance with the resolution of the Annual General Meeting of Detection Technology Plc on 27 March 2025. The total number of shares to be cancelled is 300, representing approximately 0.002 percent of all the company's shares.
The share cancellation will become effective once it has been registered in the Trade Register, estimated to be on 7 April 2025. After the cancellation, the total number of shares in Detection Technology Plc will be 14,655,630. The share cancellation does not have an effect on the company's share capital.
Detection Technology has one share series, and all shares bear equal voting rights. The company's shares are listed on the Nasdaq First North Growth Market Finland marketplace under the ticker symbol DETEC.
Detection Technology Plc
Further information
Hannu Martola, President and CEO
+358 500 449 475, hannu.martola@deetee.com
Nordea is the company's Certified Advisor under the Nasdaq First North GM rules, +358 9 5300 6774
Detection Technology is a global provider of X-ray detector solutions and services for medical, security, and industrial applications. The company's solutions range from sensor components to optimized detector subsystems with ASICs, electronics, mechanics, software, and algorithms. It has sites in Finland, China, France, India, and the US. The company's shares are listed on Nasdaq First North Growth Market Finland under the ticker symbol DETEC.
Circulation: Nasdaq Helsinki, key media, www.deetee.com
Detection Technology Plc company announcement 27 March 2025 at 18:15 (EET)
Detection Technology: Organising meeting of the Board of Directors
In its organising meeting, the Board of Directors of Detection Technology Plc has elected Henrik Roos as the Chair of the Board in accordance with the recommendation of the Shareholders' Nomination Board and Antti Vasara as the Vice Chair until the next Annual General Meeting. In addition, the Board of Directors elected members of the Remuneration and Audit Committees from among its members.
The compositions of the Board committees were decided to be as follows:
Remuneration Committee
Antti Vasara, Chair
Amy Chen
Henrik Roos
Audit Committee
Jyrki Vainionpää, Chair
Marion Björkstén
Richard Ingram
The Board of Directors assessed the independence of its members and concluded that all members are independent of the company. The members are also independent of the company's significant shareholders, apart from Marion Björkstén, who acts as a Chair of the Supervisory Board of A. Ahlström Oy, and Jyrki Vainionpää, who acts as a President and CEO of A. Ahlström Oy. The largest shareholder of Detection Technology Plc, Ahlstrom Capital BV is a group company of A. Ahlström Oy.
The Board of Directors held its organising meeting after the Annual General Meeting of Detection Technology Plc on 27 March 2025.
Further information
Hannu Martola, President and CEO
+358 500 449 475, hannu.martola@deetee.com
Nordea is the company's Certified Advisor under the Nasdaq First North GM rules, +358 9 5300 6774
Detection Technology is a global provider of X-ray detector solutions and services for medical, security, and industrial applications. The company's solutions range from sensor components to optimized detector subsystems with ASICs, electronics, mechanics, software, and algorithms. It has sites in Finland, China, France, India, and the US. The company's shares are listed on Nasdaq First North Growth Market Finland under the ticker symbol DETEC.
Distribution: Nasdaq Helsinki, key media, www.deetee.com
Detection Technology Plc company announcement 27 March 2025 at 16:30 (EET)
Resolutions of the Annual General Meeting of Detection Technology
The Annual General Meeting of Detection Technology Plc was held on 27 March 2025 in Espoo, Finland. The Annual General Meeting adopted the financial statements and resolved to discharge the members of the Board of Directors and the President and CEO from liability for the financial year 1 January - 31 December 2024.
Use of the profit shown on the balance sheet and the distribution of funds
The Annual General Meeting resolved that a dividend of EUR 0.50 per share for the financial year 2024 is paid. The dividend shall be paid to shareholders who are registered in the company's register of shareholders, maintained by Euroclear Finland Ltd, on the record date for payment, 31 March 2025. It was resolved that the dividend is paid on 7 April 2025.
The Board of Directors and the Auditor
The Annual General Meeting resolved that the Board of Directors consists of six (6) members. Marion Björkstén, Amy Chen, Richard Ingram, Henrik Roos and Jyrki Vainionpää were re-elected while Antti Vasara was elected as a new member to the Board of Directors.
Authorised Public Accounting firm KPMG Oy Ab was elected as the Auditor of the company, and Petri Kettunen, Authorised Public Accountant, will act as the Responsible Auditor.
It was resolved that an annual fixed remuneration of the members of the Board of Directors is paid as follows: annual fee of EUR 69,000 to be paid to the Chair, EUR 51,000 to the Vice Chair, and EUR 39,000 to other members of the Board of Directors. It was also resolved that the members of the Board of Directors be paid a meeting-specific fee as follows: EUR 1,000 to the Chair of the Board of Directors and EUR 500 to the members of the Board of Directors per each meeting held in the home country of the respective member, and EUR 1,500 to the Chair of the Board of Directors and EUR 1,000 to the members of the Board of Directors per each meeting held elsewhere than in the home country of the respective member.
An elected member of the Board of Directors may, at his/her discretion, choose to receive the annual fixed remuneration partly in company shares and partly in cash so that approximately 40% of the annual fixed remuneration is paid in Detection Technology Plc's shares. The number of shares forming the above remuneration portion, which would be payable in shares, will be determined based on the share value in the public trading maintained by Nasdaq Helsinki Ltd, calculated as the trade volume weighted average quotation of the share during the one-month period immediately following the date on which the interim report of January-March 2025 of the company is published.
It was resolved that the members of the Audit Committee and the Remuneration Committee would be paid a meeting fee of EUR 500 per meeting. The travel expenses of the members of the Board of Directors are compensated in accordance with the company's travel rules. It was resolved that the remuneration for the Auditor is paid according to the Auditor's reasonable invoice.
Authorization of the Board of Directors to resolve on repurchase of own shares and on a share issue and an issue of special rights entitling to shares
The Board of Directors was authorized to resolve on the repurchase of a maximum of 732,781 shares in the company in one or several tranches by using funds in the unrestricted shareholders' equity. The number corresponds to approximately 5% of the current number of all shares in the company. The own shares may be repurchased other than in proportion to the shareholdings of the shareholders, if the Board of Directors deems that there are weighty financial reasons for such directed repurchase, in public trading arranged by Nasdaq Helsinki Oy for the market price formed at the moment of purchase. The authorization revokes all previous unused authorizations on the repurchase of shares and is valid until the closing of the next Annual General Meeting, however, no longer than until 30 June 2026.
The Board of Directors was authorized to resolve on the share issue and the issuance of special rights entitling to shares as referred to in Chapter 10 Section 1 of the Finnish Limited Liability Companies Act in one or several parts, either against payment or without payment. The aggregate number of shares to be issued, including the shares to be received based on special rights, shall not exceed 1,465,563 shares, which corresponds to approximately 10% of the current number of all shares in the company. The Board of Directors may resolve to issue either new shares or to transfer treasury shares potentially held by the company.
The new shares, the special rights referred to in Chapter 10 Section 1 of the Finnish Limited Liability Companies Act and the own shares held by the company may be issued and transferred to the shareholders in proportion to their current shareholdings in the company or in deviation from the shareholders' pre-emptive rights by way of a directed issue if there is a weighty financial reason for the company to do so. The deviation from the shareholders' pre-emptive rights may be carried out for example in order to develop the company's capital structure, to finance or carry out acquisitions, investments or other business transactions, or to use the shares as a part of an incentive scheme. A directed share issue may be executed without consideration only if there is an especially weighty financial reason for the company to do so, taking into account the interests of the company and all its shareholders.
The Board of Directors may also, based on the authorization, decide on a share issue to the company itself without consideration so that the number of own shares held by the company after the issue does not exceed 10 % of all shares in the company. The own shares held by the company and its subsidiaries shall be included in the amount as set out in Chapter 15 Section 11 Subsection 1 of the Finnish Limited Liability Companies Act.
The Board of Directors is authorized to decide on all other matters related to the issuance of shares and special rights. The authorization is valid until the closing of the next Annual General Meeting, however, no longer than until 30 June 2026. The authorization revokes all previous unused authorizations of the Board of Directors to resolve on the issuance of shares and issuance of special rights entitling to shares.
Forfeiture of the shares held in the joint account and the rights carried by the shares
The company's shares were incorporated into the book-entry system in 2015. Shareholders were at the time required to request their shares to be registered in their book-entry account within the registration period (i.e. 30 January 2015 at the latest). The shares that were not registered on a book-entry account of a shareholder within the registration period, have been held on a book-entry account opened on behalf of the shareholders (Joint Account).
The Joint Account is meant for the temporary custody of the shares, until the shareholders register their shares in their own book-entry account, and a shareholder cannot exercise the rights attached to the shares before the shares have been registered on the shareholder's book-entry account. There are still shares on the Joint Account, because the owners of such shares have not made a declaration for registration since the incorporation of the shares in the book-entry system in 2015.
According to Chapter 3, Section 14 a of the Finnish Companies Act the general meeting may decide that the right to the share recorded in the book-entry system and the rights carried by it have been forfeited, if the recording of the shares has not been requested before ten years have passed from the end of the registration period and entry into force of the current Companies Act. The provisions on treasury shares apply to a forfeited share. On the date of the General Meeting, over ten years had passed from the end of the registration period of the shares on the Joint Account and entry into force of the Companies Act.
The Annual General Meeting decided on the forfeiture of the rights to all the shares entered in the Joint Account, the registration of which has not been requested in accordance with Chapter 6, Section 3 of the Act on the Book-Entry System and Settlement Activities before the decision of Annual General Meeting (27 March 2025 at 14:00 EET), as well as of the rights attached to such shares.
The Joint Account holds a total of 300 shares, corresponding to approximately 0.002 per cent of all shares in the company.
The minutes of the Annual General Meeting will be available on the company's website at www.deetee.com latest on 10 April 2025.
Detection Technology Plc
Board of Directors
Further information
Hannu Martola, President and CEO
+358 500 449 475, hannu.martola@deetee.com
Nordea is the company's Certified Advisor under the Nasdaq First North GM rules,
+358 9 5300 6774
Detection Technology is a global provider of X-ray detector solutions and services for medical, security, and industrial applications. The company's solutions range from sensor components to optimized detector subsystems with ASICs, electronics, mechanics, software, and algorithms. It has sites in Finland, China, France, India, and the US. The company's shares are listed on Nasdaq First North Growth Market Finland under the ticker symbol DETEC.
Distribution: Nasdaq Helsinki, key media, www.deetee.com
Equity Research Disclaimer
These research reports have been prepared by Evli Research Partners Plc (“ERP” or “Evli Research”). ERP is a subsidiary of Evli Plc.
None of the analysts contributing to this report, persons under their guardianship or corporations under their control have a position in the shares of the company or related securities. The date and time for any price of financial instruments mentioned in the recommendation refer to the previous trading day’s closing price(s) unless otherwise stated in the report. Each analyst responsible for the content of this report assures that the expressed views accurately reflect the personal views of each analyst on the covered companies and securities. Each analyst assures that (s)he has not been, nor are or will be, receiving direct or indirect compensation related to the specific recommendations or views contained in this report.
Companies in the Evli Group, affiliates or staff of companies in the Evli Group, may perform services for, solicit business from, hold long or short positions in, or otherwise be interested in the investments (including derivatives) of any company mentioned in the publication or report. Neither ERP nor any company within the Evli Group have managed or co-managed a public offering of the company’s securities during the last 12 months prior to, received compensation for investment banking services from the company during the last 12 months prior to the publication of the research report.
ERP has signed an agreement with the issuer of the financial instruments mentioned in the recommendation, which includes production of research reports. This assignment has a limited economic and financial impact on ERP and/or Evli. Under the assignment ERP performs services including, but not limited to, arranging investor meetings or –events, investor relations communication advisory and production of research material. ERP or another company within the Evli Group does not have an agreement with the company to perform market making or liquidity providing services. For the prevention and avoidance of conflicts of interests with respect to this report, there is an information barrier (Chinese wall) between Investment Research and Corporate Finance units concerning unpublished investment banking services to the company. The remuneration of the analyst(s) is not tied directly or indirectly to investment banking transactions or other services performed by Evli Plc or any company within Evli Group.
This report is provided and intended for informational purposes only and may not be used or considered under any circumstances as an offer to sell or buy any securities or as advice to trade any securities.
This report is based on sources ERP considers to be correct and reliable. The sources include information providers Reuters and Bloomberg, stock-exchange releases from the companies and other company news, Statistics Finland and articles in newspapers and magazines. However, ERP does not guarantee the materialization, correctness, accuracy or completeness of the information, opinions, estimates or forecasts expressed or implied in the report. In addition, circumstantial changes may have an influence on opinions and estimates presented in this report. The opinions and estimates presented are valid at the moment of their publication and they can be changed without a separate announcement. Neither ERP nor any company within the Evli Group are responsible for amending, correcting or updating any information, opinions or estimates contained in this report. Neither ERP nor any company within the Evli Group will compensate any direct or consequential loss caused by or derived from the use of the information represented in this publication.
All information published in this report is for the original recipient’s private and internal use only. ERP reserves all rights to the report. No part of this publication may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in any retrieval system of any nature, without the written permission of ERP.
This report or its copy may not be published or distributed in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore or South Africa. The publication or distribution of this report in certain other jurisdictions may also be restricted by law. Persons into whose possession this report comes are required to inform themselves about and to observe any such restrictions.
Evli Plc is not registered as a broker-dealer with the U. S. Securities and Exchange Commission (“SEC”), and it and its analysts are not subject to SEC rules on securities analysts’ certification as to the currency of their views reflected in the research report. Evli is not a member of the Financial Industry Regulatory Authority (“FINRA”). It and its securities analysts are not subject to FINRA’s rules on Communications with the Public and Research Analysts and Research Reports and the attendant requirements for fairness, balance and disclosure of potential conflicts of interest. This research report is only being offered in U.S. by Auerbach Grayson & Company, LLC (Auerbach Grayson) to Major U.S. Institutional Investors and is not available to, and should not be used by, any U.S. person or entity that is not a Major U.S. Institutional Investor. Auerbach Grayson is a broker-dealer registered with the U.S. Securities and Exchange Commission and is a member of the FINRA. U.S. entities seeking more information about any of the issuers or securities discussed in this report should contact Auerbach Grayson. The securities of non-U.S. issuers may not be registered with or subject to SEC reporting and other requirements.
ERP is not a supervised entity but its parent company Evli Plc is supervised by the Finnish Financial Supervision Authority.
Company Facts
Financial targets
At least 10% annual sales growth and EBIT margin at or above 15% in the medium term
Schedule analyst call
For professional investors wishing to discuss the case, please book a complimentary analyst call
Book a call